Pfizer’s multi-year lows reflect headwinds, lack of catalysts, and fading appeal to both growth and defensive investors. Read ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Recursion Pharmaceuticals (RXRX – Research ...

The Trump administration’s remaking of HHS — in a matter of weeks — is sparking basic questions about how parts of the agency ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

The Heart Failure Drugs Market is poised for a transformative decade between 2025 and 2035. As heart failure continues to ...

Thursday’s top news, all in one place.Vaccines called “filth” by MP Kotlár Peter Kotlár, the Slovak government’s commissioner for investigating coronavirus pandemic management, accused leading ...

Shares of Pfizer Inc. PFE slipped 4.00% to $21.59 Thursday, on what proved to be an all-around dismal trading session for the ...

A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White ...

Here are six new shortages and discontinuations for April, according to drug supply databases from the FDA and the American ...

Five years ago, volunteers rolled up their sleeves in the first clinical trial of a vaccine against COVID-19, as the new ...

Health systems are seeing early success with AI-powered tools. Here is a look at how AI is paying off at four health systems, as reported by Becker’s: Mass General Brigham, based in Somerville, Mass., ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...